Skip to content

9 octobre 2013

  • by

Alethia Biothérapeutiques annonce la délivrance d’un brevet concernant l’utilisation d’anticorps anti-Siglec-15

Alethia PR 131009 FR

Leave a Reply

Your email address will not be published. Required fields are marked *